冠心病；外科治疗；激光心肌血运重建术。
Coronary heart disease; Bypass surgery; Transmyocardial laser revascularization.
所有造成死亡或经受心肌血运重建术被认为是竞争的风险事件。
All-cause death and undergoing revascularization procedures were considered competing risk events.
观察经皮激光打孔心肌血运重建术治疗顽固性心绞痛的临床疗效。
Objective to observe the clinical efficacy of percutaneous laser myocardial revascularization (PLMR) on the treatment of angina pectoris.
目的探讨经皮激光心肌血运重建术（PMR）治疗心肌缺血的机制。
Objective To evaluate the cardiac angiogenesis after percutaneous myocardial laser revascularization (PMR).
选择合适的评价方法，对那些有存活心肌的患者进行合理的血运重建术，从而达到改善患者预后的目的。
It is very important to select suitable method for evaluation of the patients who have viable myocardium, which can provide scientific evidences for reasonable revascularization to improve prognosis.
经心肌激光打孔血运重建术（TMLR）是一种治疗冠心病的外科新方法，其麻醉也具有与其它心血管手术不同的特点。
Transmyocardial laser revascularization (TMLR) is a new surgical method of curing coronary artery disease. Anesthesia for TMLR is quite different from other cardiovascular operations.
他汀药物的治疗与糖尿病患者中心肌梗死或冠心病死亡、冠状动脉血运重建术、卒中发生的显著下降有关。
Statin therapy was also associated with significant reductions in MI or coronary death, coronary revascularization, and stroke among the diabetic participants.
30天和一年的住院期间，其主要结局是缓慢流动/无复流现象（SF-NR）的发生，临床终点包括死亡、心肌梗死（MI）、靶病变血管血运重建术（TVR）和主要心脏不良事件（MACE）。
The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.
30天和一年的住院期间，其主要结局是缓慢流动/无复流现象（SF-NR）的发生，临床终点包括死亡、心肌梗死（MI）、靶病变血管血运重建术（TVR）和主要心脏不良事件（MACE）。
The primary outcome was the occurrence of SF-NR Clinical endpoints included death, MI, target vessel revascularization (TVR), and MACE during the hospitalization period, 30 days and at 1 year.
应用推荐